Trial Profile

An Investigator-initiated, Prospective, Randomized, Open Label, Parallel Study to Explore and Evaluate the Therapeutic Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients With Mild Cognitive Impairment.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary) ; Linagliptin (Primary) ; Liraglutide (Primary)
Indications Cognition disorders
Focus Therapeutic Use
Acronyms LIGHT-MCI

21 May 2025 Planned End Date changed from 31 Dec 2027 to 31 Dec 2025.
21 May 2025 Planned primary completion date changed from 31 Dec 2026 to 31 Dec 2025.
21 May 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com